Clearmind Medicine CMND 深 沪
等待开盘 01-29 09:30:00 美东时间
2.52
-0.160
-5.97%
华盛通- 最 高2.62
- 今 开2.62
- 成交量 5.66万股
- 最 低 2.41
- 昨 收 2.68
- 总市值 377.95万
- 52周最高 58.00
- 市盈率 静 --
- 换手率 3.78%
- 52周最低 1.743
- 委 比 98.25%
- 总股本 149.98万
- 历史最高 7320.00
- 量 比 1.41
- 振 幅 7.84%
- 历史最低 1.84
- 每 手 1
- 风险率 15.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Clearmind Medicine Completes Treatment For All Patients In Second Cohort Of Ongoing FDA-Approved Phase I/IIa Clinical Trial Evaluating CMND-100 For AUD Treatment
Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major
01-14 21:57
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
Clearmind Medicine Inc. announced the successful completion of treatment for the second cohort in its Phase I/IIa clinical trial of CMND-100 for Alcohol Use Disorder. The six-patient cohort, recruited from leading medical centers, completed the trial following positive results from the first cohort, which showed favorable safety and efficacy signals. The company expects to release top-line results from the second cohort in the coming months.
01-14 13:55
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 19.2% to $1...
01-09 20:05
Dr. Adi Zuloff-Shani, CEO Of Clearmind Medicine Says "Looking Ahead To 2026, Clearmind Remains Focused On Advancing Its Pipeline, Generating Additional Clinical Data, And Exploring Strategic Opportunities To Maximize Shareholder Value And Patient Impact"
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented: "2025 has been a pivotal year for Clearmind as we transitioned into a clinical-stage company, executing on our multinational trial. These achievements
2025-12-24 22:16
Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth
<p>Clearmind Medicine Inc. reported significant progress in 2025 for its lead candidate CMND-100, a non-hallucinogenic compound targeting Alcohol Use Disorder. The FDA-approved Phase I/IIa trial advanced with site activations at Yale, Johns Hopkins, and Israeli medical centers. Positive safety results, no serious adverse events, and successful dosing in multiple cohorts were achieved. The Data and Safety Monitoring Board approved continuation of ...
2025-12-24 14:15
Why Are Shares Of Atossa Therapeutics Up Today?
Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know.
2025-12-12 01:26
Clearmind Medicine shares are trading lower after the company announced a 1-for-40 reverse share split.
Clearmind Medicine shares are trading lower after the company announced a 1-for...
2025-12-11 05:30
Clearmind Medicine Announces 1-for-40 Reverse Share Split
Clearmind Medicine Inc. (NASDAQ: CMND) announces a 1-for-40 reverse share split to regain compliance with the Nasdaq Minimum Bid Price Rule, effective December 15, 2025. The split was approved by the board on November 12, 2025. This will reduce the outstanding common shares from 59,991,852 to approximately 1,499,796, with fractional shares rounded up. All outstanding options and warrants will be proportionally adjusted. The company focuses on dev...
2025-12-10 21:15
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers GT Biopharma (NASDAQ:GTBP) shares moved upwards by 6.6% to $0.65 durin...
2025-12-06 05:05
Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial
Clearmind Medicine Inc. recently reported three key milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100, an oral therapy targeting Alcohol Use Disorder (AUD). These include positive results from the first cohort, DSMB approval to continue the trial, and the启动of enrollment at a new clinical site in Israel. AUD affects over 28 million adults in the U.S., causing significant societal and economic impacts. CMND-100 aims to reduce a...
2025-12-01 13:56
